why choose us

First received: July 21, 2023

Clinical Trial: A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Non-alcoholic Fatty Liver Disease

Study Type: INTERVENTIONAL


Official Title: Phase Ib Trial to Assess Safety and Tolerability of Multiple Subcutaneous Doses of BI 3006337 in Patients With Overweight or Obesity and Hepatic Steatosis

Brief Summary: This study is open to adults with overweight or obesity who also have fatty liver disease.The purpose of this study is to find the highest dose of BI 3006337 that people with overweight or obesity and with fatty liver disease can tolerate.Participants are divided into 4 groups of equal size randomly, which means by chance.Different doses of BI 3006337 are given to participants in each group.Participants in each group receive an injection of either BI 3006337 or placebo once a week.Placebo injections look like BI…

Read more